Roundup, deals, Life Sciences Bruce V. Bigelow wrote: It’s hard for any company to raise capital in this recession, but several San Diego life sciences startups disclosed last week they had done just that. A few bright spots also appeared during a local seminar on mergers and acquisitionsR...

Roundup, deals, Life Sciences Bruce V. Bigelow wrote: The best part about last week’s deals and biztech news was that so much of it amounted to the first act in a continuing drama. Will the deal go through? Will that drug get approved? Stay tuned… Who needs TV soaps when a corporate buyo...

Biotech, Hepatitis C, Life Sciences Luke Timmerman wrote: An early peek at data from Anadys Pharmaceuticals (NASDAQ: ANDS) suggests the company may have a promising new drug in the works for hepatitis C. The San Diego-based biotech is announcing results today from the first eight patients with the c...